scholarly journals Trends in molecular characteristics and antimicrobial resistance of group B streptococci: a multicenter study in Serbia, 2015–2020

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Dusan Kekic ◽  
Ina Gajic ◽  
Natasa Opavski ◽  
Milan Kojic ◽  
Goran Vukotic ◽  
...  
Keyword(s):  
Antimicrobial Resistance ◽  
Late Onset ◽  
Group B Streptococcus ◽  
Neonatal Morbidity ◽  
Disease Rate ◽  
Molecular Characteristics ◽  
Group B Streptococci ◽  
Live Births ◽  
Invasive Infections ◽  
Group B

AbstractGroup B Streptococcus (GBS) is a major cause of neonatal morbidity and mortality. Serbia has not fully implemented preventive measures against GBS neonatal diseases. Therefore, we aimed to assess the maternal GBS colonisation and invasive neonatal disease rate, to reveal the trends of antimicrobial resistance and serotype distribution of GBS from various patient groups. Randomly selected non-invasive (n = 991) and all invasive GBS (n = 80) collected throughout Serbia from 2015 to 2020 were tested for antimicrobial susceptibility, capsular typing, and hvgA detection. Overall, 877/5621 (15.6%) pregnant women were colonised with GBS. Invasive GBS infections incidence in infants (0.18/1000 live births) showed a decreasing trend (0.3 to 0.1/1000 live births). Type III was overrepresented in infants with invasive infections (n = 35, 58.3%), whereas type V predominated among colonised adults (n = 224, 25.5%) and those with noninvasive (n = 37, 32.5%) and invasive infections (n = 8, 40%). The hypervirulent clone III/ST17 was highly associated with invasive infections (n = 28, 35%), particularly late-onset disease (n = 9, 47.4%), showing an increase from 12.3 to 14.8%. The GBS resistance to erythromycin and clindamycin was 26.7% and 22.1%, respectively, with an upward trend. The emergence of the hypervirulent clone III/ST17 and the escalation in GBS resistance highlight an urgent need for continuous monitoring of GBS infections.

scholarly journals Molecular Characteristics of Group B Streptococci Isolated from Adults with Invasive Infections in Japan

2016 ◽  
Vol 54 (11) ◽  
pp. 2695-2700 ◽  
Author(s):  
Miyuki Morozumi ◽  
Takeaki Wajima ◽  
Misako Takata ◽  
Satoshi Iwata ◽  
Kimiko Ubukata
Keyword(s):  
Amino Acid ◽  
Group B Streptococcus ◽  
Antibiotic Use ◽  
Molecular Characteristics ◽  
Amino Acid Substitutions ◽  
Group B Streptococci ◽  
Content Type ◽  
Invasive Infections ◽  
Primary Focus ◽  
Group B

Streptococcus agalactiae(group B streptococcus) isolates (n= 443) obtained from Japanese adults with invasive infections between April 2010 and March 2013 were analyzed for capsular serotype, multilocus sequence type (ST), antibiotic susceptibility, and resistance genes. Among these cases, bacteremia without primary focus was the most common variety of infection (49.9%), followed by cellulitis (12.9%) and pneumonia (9.0%). Concerning patient age (18 to 59, 60 to 69, 70 to 79, 80 to 89, and 90 years old or older), the incidence of pneumonia increased in patients in their 70s and 80s (P< 0.001), while younger patients (18 to 59 and 60 to 69 years old) were more likely to have abscesses (P< 0.05). The mortality rate was 10.2% for all ages. The most common capsular serotype was Ib (39.5%), followed by V (16.0%), III (13.8%), VI (9.5%), and Ia (8.6%). The main ST of serotype Ib strains was ST10, which belonged to clonal complex 10 (88.0%). The predominant clonal complexes of serotypes V and III, respectively, were 1 (78.9%) and 19 (75.4%). Among these isolates, 9 strains (2.0%) were identified as group B streptococci with reduced penicillin susceptibility, reflecting amino acid substitutions in penicillin-binding protein 2X (PBP2X). In addition, 19.2% of all strains possessedmef(A/E),erm(A), orerm(B) genes, which mediate macrolide resistance, while 40.2% of strains were resistant to quinolones resulting from amino acid substitutions in GyrA and ParC. Our data argue strongly for the continuous surveillance of microbial characteristics and judicious antibiotic use in clinical practice.

scholarly journals Neonatal Sepsis: Clinical Considerations

2017 ◽  
Vol 07 (01) ◽  
pp. e54-e59 ◽  
Author(s):  
S. Blatt ◽  
M. Schroth
Keyword(s):  
Neonatal Sepsis ◽  
Late Onset ◽  
Rapid Development ◽  
Group B Streptococcus ◽  
Neonatal Morbidity ◽  
Screening Tests ◽  
Late Onset Sepsis ◽  
Early Onset Sepsis ◽  
Clinical Considerations ◽  
Group B

AbstractUnspecific symptoms and rapid development of sepsis up to septic shock from systemic inflammatory response syndrome (SIRS) are well-known, important issues in neonatology. A common cause is the infection by Streptococcus agalactiae (Group B Streptococcus [GBS]) or Escherichia coli, which contributes significantly to neonatal morbidity and mortality. Whereas early-onset sepsis is normally derived from mother during birth, late-onset sepsis can be transmitted by the environment. Management of neonatal sepsis includes the maintenance of cardiovascular and pulmonary function besides antibiotic therapy. Due to the fact that until today, there are no reliable screening tests for detecting early sepsis, clinical assessment is considered to be of utmost importance.

scholarly journals An empirical Bayes method for serotype case-carrier ratios, with an application to Group B streptococcus

2018 ◽  
Author(s):  
Joseph A. Lewnard ◽  
Lauren A. Cowley
Keyword(s):  
Empirical Bayes ◽  
Ad Hoc ◽  
Late Onset ◽  
Group B Streptococcus ◽  
Invasive Disease ◽  
Random Effects Model ◽  
Bayes Method ◽  
Disease States ◽  
Invasive Infections ◽  
Group B

ABSTRACTBackgroundCase-carrier ratios quantifying the relative pathogenicity of serotypes can inform vaccine formulations for antigenically-diverse pathogens. However, sparse serotype-specific counts in epidemiologic datasets may undermine such analyses, most notably for rare serotypes that pose emergence risks in vaccinated populations. This challenge is well-illustrated in Group B streptococcus (GBS), where serotype III dominates in both carriage and disease.MethodsWe develop an empirical Bayes random-effects model based on conjugate Dirichlet-multinomial distributions of serotype frequencies in carriage and disease states. We validate the model using simulated datasets, and apply it to data from 15 paired sets of GBS isolates from intrapartum rectovaginal colonization (n=3403) and neonatal invasive disease (NID; n=1088), 16 from blood (n=2352) and cerebrospinal fluid (n=780) neonatal specimens, and 3 from fatal (n=173) and non-fatal (n=1684) neonatal invasive infections.ResultsOur method accurately recovers parameters in simulated datasets. Using this approach, we confirm that GBS serotype III exhibits the greatest invasiveness, followed by serotype Ia with a 75.3% (95%CrI: 43.7-93.8%) lower estimate. Enhanced invasiveness of serotypes III and Ia is most evident in late-onset disease. Non–hexavalent-vaccine serotypes, which are rare in carriage and disease, generally show lower invasiveness; serotype IX/non-typeable GBS, the most prevalent cause of non–vaccine-preventable disease, is 98.7% (81.7-99.9%) and 94.2% (13.9-99.6%) less invasive than serotypes III and Ia, respectively.ConclusionsWe present a strategy for measuring associations of serotype with carrier and disease states in the presence of sparse counts, avoiding biases that exist in common ad-hoc approaches.

scholarly journals Epidemiological Characterization of Group B Streptococcus Infections in Alberta, Canada: An Update from 2014 to 2020

2021 ◽  
Author(s):  
Angela Ma ◽  
L. Alexa Thompson ◽  
Thomas Corsiatto ◽  
Donna Hurteau ◽  
Gregory J. Tyrrell
Keyword(s):  
Early Onset ◽  
Late Onset ◽  
Group B Streptococcus ◽  
Content Type ◽  
Adult Disease ◽  
Invasive Infections ◽  
Group B ◽  
Epidemiological Characterization

This work describes the epidemiology of invasive infections caused by the bacterium group B Streptococcus (GBS) in Alberta, Canada. We show that rates of invasive GBS disease have increased from 2014 to 2020 for both adult disease and late-onset disease in neonates, whereas the rate of early onset disease in neonates has decreased. We also show that the rate of resistance to erythromycin (an antibiotic used to treat GBS) has also increased in this time.

Group B Streptococcus

1986 ◽  
Vol 7 (S2) ◽  
pp. 135-137 ◽  
Author(s):  
Charles S.F. Easmon
Keyword(s):  
United States ◽  
Early Onset ◽  
Western Europe ◽  
Late Onset ◽  
Group B Streptococcus ◽  
The United States ◽  
Group B Streptococci ◽  
Neonatal Group ◽  
Group B ◽  
Portal Of Entry

Over the past 25 years group B streptococci have become established as one of the main bacterial pathogens of the neonate in Western Europe and the United States. The attack rate of 0.25/1,000 live births found by Mayon White in Great Britain1 appears typical of many European countries. However, in some centers in the United States attack rates can be over 10 times higher.Two types of neonatal group B streptococcus (GBS) diseases exist, “early” and “late” onset. Early onset disease usually presents within the first few days of life. Often the most serious infections are present at birth or seen within a few hours. Early onset disease presents with pneumonia, respiratory distress and shock. Bacteremia is normally present and meningitis may occur. Mortality is high (50% to 75%). The portal of entry is probably the respiratory tract. Infants normally acquire the infecting organism from their mothers. Heavy maternal and infant colonization, prolonged rupture of membranes, prematurity, and obstetric complications are all risk factors.Delayed onset disease, as its name suggests, presents after the first week of life, primarily with bacteremia and meningitis. Mortality is much lower than for the early onset form, but still appreciable for a bacterial infection (14% to 18%). Its epidemiology is uncertain.

scholarly journals Neonatal Group B streptococcal osteomyelitis and suppurative arthritis: A case report

2021 ◽  
Vol 35 ◽  
pp. 117-120
Author(s):  
Ashwath Duraiswamy ◽  
Veerappan Somu
Keyword(s):  
Neonatal Sepsis ◽  
Late Onset ◽  
Group B Streptococcus ◽  
Neonatal Morbidity ◽  
Sternoclavicular Joint ◽  
Unusual Site ◽  
Late Onset Sepsis ◽  
Focal Infection ◽  
Neonatal Group ◽  
Group B

Neonatal sepsis contributes significantly to neonatal morbidity and mortality. Group B streptococcus (GBS) is not a frequent cause of neonatal sepsis in India. Late onset sepsis by GBS presenting as focal infection like osteomyelitis is seen in only 3% of the total GBS sepsis profile in neonates. Here, we report a rare case of neonatal osteomyelitis with septic arthritis caused by GBS at an unusual site, the clavicle and sternoclavicular joint.

Associations between capsular serotype, multilocus sequence type, and macrolide resistance inStreptococcus agalactiaeisolates from Japanese infants with invasive infections

2013 ◽  
Vol 142 (4) ◽  
pp. 812-819 ◽  
Author(s):  
M. MOROZUMI ◽  
T. WAJIMA ◽  
Y. KUWATA ◽  
N. CHIBA ◽  
K. SUNAOSHI ◽  
...  
Keyword(s):  
Clonal Complex ◽  
Vaccine Development ◽  
Late Onset ◽  
Group B Streptococcus ◽  
Sequence Type ◽  
Macrolide Resistance ◽  
Invasive Infections ◽  
Resistant Strains ◽  
Group B ◽  
Sequence Types

SUMMARYStreptococcus agalactiae(group B streptococcus; GBS) isolates (n = 150) from infants with invasive infections between 2006 and 2011 were analysed for capsular serotype, multilocus sequence type, and antibiotic susceptibility. In cases with late-onset disease (n = 115), primary meningitis was predominant (62·6%), but represented only 39·1% in cases with early-onset disease (n = 23). The most common serotype was III (58·7%), followed by Ia (21·3%) and Ib (12·7%). Sequence types (STs) of serotype III strains included ST17 (50·0%), ST19 (26·1%), ST335 (18·2%), ST27 (4·5%), and ST1 (1·1%). Predominant STs of serotypes Ia and Ib were ST23 (81·3%) and ST10 (84·2%), respectively. No penicillin-resistant strains were detected, but 22·0% of strains hadmef(A/E),erm(A), orerm(B) genes, which mediate macrolide resistance. A new ST335, possessing anmef(A/E) gene belonging to clonal complex 19 gradually increased in frequency. Improved prevention of invasive GBS infections in infants requires timely identification, and ultimately vaccine development.

scholarly journals Epidemiology of Invasive Group B Streptococcal Disease in Alberta, Canada, from 2003 to 2013

2016 ◽  
Vol 54 (7) ◽  
pp. 1774-1781 ◽  
Author(s):  
Areej Alhhazmi ◽  
Donna Hurteau ◽  
Gregory J. Tyrrell
Keyword(s):  
Capsular Polysaccharide ◽  
Late Onset ◽  
Disease Incidence ◽  
Invasive Disease ◽  
Erythromycin Resistance ◽  
Surveillance Period ◽  
Group B Streptococci ◽  
Screening Programs ◽  
Live Births ◽  
Group B

Group B streptococci (GBS) cause severe invasive disease in both neonates and adults. Understanding the epidemiology of GBS provides information that can include determining disease prevalence rates in defined populations and geographic regions, documenting the success of GBS screening programs, and understanding antimicrobial susceptibility patterns. In Alberta, only neonatal invasive GBS (iGBS) disease is notifiable to health authorities. We performed a surveillance study of iGBS in Alberta, Canada, from 2003 to 2013. Over the 11-year period, the disease incidence rate increased from a low of 3.92 cases/100,000 population to a high of 5.99 cases/100,000 population. The capsular polysaccharide serotypes (CPSs) found were CPS III (20.3%), CPS V (19.1%), CPS Ia (18.9%), CPS Ib (12.7%), CPS II (11.1%), CPS IV (6.3%), and nontypeable GBS (9.4%). Rates of early-onset disease (0 to 7 days) increased from 0.15 cases/1,000 live births (in 2003) to 0.34 cases/1,000 live births (in 2013). Rates of late-onset disease (>7 to 90 days) also rose, from 0.15 cases/1,000 live births (in 2003) to 0.39 cases/1,000 live births (in 2013). Alberta also experienced an increase in CPS IV isolates, from 2 cases (in 2003) to 24 cases (in 2013), of which the majority werehvgApositive (86.6%). The predominant sequence type (ST) in 2013 was ST459. Erythromycin resistance rose from 23.6% to 43.9% (in 2013). Clindamycin resistance also increased, from 12.2% to 32.5%. In summary, Alberta, Canada, has experienced an increase in GBS disease; the increase includes both neonatal and adult disease. CPS IV cases also notably increased during the surveillance period, as did resistance to erythromycin and clindamycin.

Sign in / Sign up

Export Citation Format

Share Document